Critical Comparison: Bone Biologics (NASDAQ:BBLG) & Heart Test Laboratories (NASDAQ:HSCS)

Bone Biologics (NASDAQ:BBLG) and Heart Test Laboratories (NASDAQ:HSCS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Institutional and Insider Ownership

34.3% of Bone Biologics shares are owned by institutional investors. Comparatively, 17.2% of Heart Test Laboratories shares are owned by institutional investors. 13.0% of Bone Biologics shares are owned by insiders. Comparatively, 2.7% of Heart Test Laboratories shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for Bone Biologics and Heart Test Laboratories, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bone Biologics	0	0	0	0	N/A
Heart Test Laboratories	0	0	1	0	3.00

Heart Test Laboratories has a consensus price target of $15.00, suggesting a potential upside of 333.53%. Given Heart Test Laboratories’ higher possible upside, analysts clearly believe Heart Test Laboratories is more favorable than Bone Biologics.

Earnings & Valuation

This table compares Bone Biologics and Heart Test Laboratories”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bone Biologics	N/A	N/A	-$8.95 million	N/A	N/A
Heart Test Laboratories	$18,600.00	122.03	-$6.61 million	($48.00)	-0.07

Heart Test Laboratories has higher revenue and earnings than Bone Biologics.

Profitability

This table compares Bone Biologics and Heart Test Laboratories’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bone Biologics	N/A	-154.18%	-130.06%
Heart Test Laboratories	N/A	-144.12%	-94.48%

Volatility and Risk

Bone Biologics has a beta of 0.4, suggesting that its stock price is 60% less volatile than the S&P 500. Comparatively, Heart Test Laboratories has a beta of 3.16, suggesting that its stock price is 216% more volatile than the S&P 500.

Summary

Heart Test Laboratories beats Bone Biologics on 7 of the 9 factors compared between the two stocks.

About Bone Biologics

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

About Heart Test Laboratories

Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.